Syngen BiotechLtd Balance Sheet Health
Financial Health criteria checks 6/6
Syngen BiotechLtd has a total shareholder equity of NT$2.2B and total debt of NT$237.7M, which brings its debt-to-equity ratio to 10.9%. Its total assets and total liabilities are NT$3.0B and NT$818.7M respectively. Syngen BiotechLtd's EBIT is NT$305.1M making its interest coverage ratio 40.9. It has cash and short-term investments of NT$228.3M.
Key information
10.9%
Debt to equity ratio
NT$237.73m
Debt
| Interest coverage ratio | 40.9x |
| Cash | NT$228.31m |
| Equity | NT$2.18b |
| Total liabilities | NT$818.68m |
| Total assets | NT$3.00b |
Recent financial health updates
Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?
Mar 25
Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly
Dec 16
Recent updates
Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?
Mar 25Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?
Feb 25Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?
Feb 04Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 14Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly
Dec 16Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?
Nov 25Financial Position Analysis
Short Term Liabilities: 8279's short term assets (NT$1.0B) exceed its short term liabilities (NT$471.7M).
Long Term Liabilities: 8279's short term assets (NT$1.0B) exceed its long term liabilities (NT$346.9M).
Debt to Equity History and Analysis
Debt Level: 8279's net debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: 8279's debt to equity ratio has reduced from 17.5% to 10.9% over the past 5 years.
Debt Coverage: 8279's debt is well covered by operating cash flow (143.8%).
Interest Coverage: 8279's interest payments on its debt are well covered by EBIT (40.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 02:50 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syngen Biotech Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hsiu Chi Lin | Masterlink Securities Corp. |